Cambria Biosciences Announces Collaboration with Pfizer Animal Health in Antiparasitic Drug Discovery

WOBURN, Mass.--(BUSINESS WIRE)--Cambria Biosciences LLC, a Boston-area CNS drug discovery company, today announced a research collaboration agreement with Pfizer Animal Health to guide the discovery and development of new classes of safe and effective antiparasitic drug products. Cambria Biosciences will use its chemical genetics platform to elucidate the molecular targets — and important functional sites within those targets — that have responded to Pfizer’s candidate parasiticidal compounds. The compounds have potentially novel modes of action that could overcome the resistance that parasites have developed to many current medicines.